ENTPD1 and neoplasm: BP1202-NF2, a glycosylated variant of the anti-CD39 antibody, depletes CD39high Tregs through antibody-dependent cellular cytotoxicity, while simultaneously enhancing antigen-specific cytotoxic T lymphocyte responses, thereby promoting anti-tumor immunity [242].